FDA accepts Immune Pharmaceuticals’ IND for Bertilimumab to treat bullous pemphigoid
Bullous pemphigoid is known to be associated with increased eotaxin-1 levels in serum and blister fluids. Immune recently started a Phase IIa open label clinical trial in bullous
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.